Literature DB >> 15120093

A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.

Gloria E Meredith1, Glenda M Halliday, Susan Totterdell.   

Abstract

The pace of development of new animal models of Parkinson's disease (PD) has increased dramatically in the recent past, primarily because of the identification of the protein, alpha-synuclein, in Lewy bodies in both idiopathic and familial PD. This discovery has allowed the production of transgenic models that incorporate a form of human, mutant alpha-synuclein from rare familial cases, and has enabled the search for Lewy-body-like aggregations of this protein in toxin-induced models. Indeed, alpha-synuclein-positive inclusions, some of which bear strong resemblance to Lewy bodies, have now been recognized and their formation investigated in several different, environmentally-induced and transgenic models. Nevertheless, these data have yet to provide a uniform theory of inclusion pathogenesis for PD. The aim of this review is not only to summarize the findings to date on alpha-synuclein-immunopositive inclusion bodies, including some new information on Lewy bodies, but also provide a concise viewpoint on their origin and formation in animal models. We will provide evidence for a predicted series of intracellular events that underlie inclusion formation. Triggered by oxidative and metabolic stress, chronic, toxin-treated animals, rather than transgenic models transfected with human alpha-synuclein, eventually produce inclusion bodies that most closely resemble early stages of Lewy bodies. Elucidating the common mechanisms in animal models is a first step towards understanding the role of Lewy bodies and their formation in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120093     DOI: 10.1016/j.parkreldis.2004.01.001

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

Review 1.  On the key role played by altered protein conformation in Parkinson's disease.

Authors:  L F Agnati; E Baldelli; N Andreoli; A S Woods; V Vellani; D Marcellino; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

Review 2.  Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.

Authors:  Gloria E Meredith; Susan Totterdell; Judith A Potashkin; D James Surmeier
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

Review 3.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

4.  Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.

Authors:  Lonnie Schneider; Jianhua Zhang
Journal:  Mol Neurodegener       Date:  2010-04-13       Impact factor: 14.195

Review 5.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

6.  Quantification of Paraquat, MPTP, and MPP+ in brain tissue using microwave-assisted solvent extraction (MASE) and high-performance liquid chromatography-mass spectrometry.

Authors:  Bozena Winnik; Dana B Barr; Mona Thiruchelvam; M Angela Montesano; Eric K Richfield; Brian Buckley
Journal:  Anal Bioanal Chem       Date:  2009-07-19       Impact factor: 4.142

7.  Molecular evidence of impaired iron metabolism and its association with Parkinson's disease progression.

Authors:  Haitao Chi; Wei Tang; Ying Bai
Journal:  3 Biotech       Date:  2020-03-19       Impact factor: 2.406

8.  Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease.

Authors:  G E Meredith; S Totterdell; M Beales; C K Meshul
Journal:  Exp Neurol       Date:  2009-06-11       Impact factor: 5.330

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease.

Authors:  Silke Nuber; Molly Rajsombath; Georgia Minakaki; Jürgen Winkler; Christian P Müller; Maria Ericsson; Barbara Caldarone; Ulf Dettmer; Dennis J Selkoe
Journal:  Neuron       Date:  2018-10-10       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.